The University of Bayreuth's Biomaterials research group has, for the first time, successfully applied the CRISPR-Cas9 ...

At stake in the ongoing patent dispute over the gene-editing tool are rights to the most important new biotechnology of the age and credit for inventing it. The CRISPR patents are back in play.

Some biotechnology companies, such as CRISPR Therapeutics (NASDAQ: CRSP), hope to use gene editing technology to treat, or even cure, diseases that existing drugs cannot. CRISPR Therapeutics ...

The latest price target for CRISPR Therapeutics (NASDAQ:CRSP) was reported by Barclays on May 9, 2025. The analyst firm set a price target for $42.00 expecting CRSP to rise to within 12 months (a ...

The CRISPR biotech is now shelving the autoimmune program and slashing staff in order to focus its resources and its finances on the two lead cancer programs, whose data readouts have been delayed ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene therapy product for treating sickle cell disease, Casgevy, faces ...

Our group applies structural (cryo-EM, x-ray crystallography and NMR), biochemical and biophysical methods together with functional studies to investigate macromolecular-mediated recognition, ...

Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline. CRISPR Therapeutics (NasdaqGM:CRSP) recently announced its Q1 2025 earnings, reporting a 71% ...

CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...